Skip to content

Study · Not a test of the peptide alone · 2026

4 results

Mitochondria-Targeted Liposomes Boost Thermogenesis for Adipose Tissue Regulation.

Tian S, Xie H, Zhong Q, Sun C, Yuan P, Xu F, Lu L, Cao J, Li M, Li H

Advanced healthcare materials11 Apr 2026

PMID41964318 (opens in a new tab)DOI10.1002/adhm.202505925 (opens in a new tab)PepBankPUB-41964318
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Mechanism

    In obese mice, treatment with the AE@PEP-Lip liposomes improved mitochondrial morphology.

    In plain wordsIn obese mice, the liposome treatment improved the shape of mitochondria in fat tissue.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Not applicableMitochondrial morphology
    Study

    mousen: not reported in source

    obese mice
    Outcome group
    Mitochondrial function · Metabolic and weight

    Source sentences

    Summary
    In obese mice, treatment with AE@PEP-Lip improved mitochondrial morphology and function and induced browning characteristics.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Mechanism

    In obese mice, treatment with the AE@PEP-Lip liposomes improved mitochondrial function.

    In plain wordsIn obese mice, the liposome treatment improved how well mitochondria work.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial function
    Study

    mousen: not reported in source

    obese mice
    Outcome group
    Mitochondrial function · Metabolic and weight

    Source sentences

    Summary
    In obese mice, treatment with AE@PEP-Lip improved mitochondrial morphology and function and induced browning characteristics.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  3. 03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Mechanism

    In obese mice, treatment with the AE@PEP-Lip liposomes induced browning characteristics.

    In plain wordsIn obese mice, the liposome treatment made fat tissue take on features of calorie-burning brown fat.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseBrowning characteristics
    Study

    mousen: not reported in source

    obese mice
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight

    Source sentences

    Summary
    In obese mice, treatment with AE@PEP-Lip improved mitochondrial morphology and function and induced browning characteristics.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  4. 04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In a porcine model, the AE@PEP-Lip liposomes showed potential for reducing localized fat deposition.

    In plain wordsIn pigs, the liposome treatment showed potential to reduce fat build-up at one body site.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseLocalized fat deposition
    Study

    pign: not reported in source

    porcine model
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Moreover, we demonstrated the clinical application potential of AE@PEP-Lip in reducing localized fat deposition using a porcine model.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.